Trousdale M D, Robin J B, Stebbing N
Curr Eye Res. 1987 Jan;6(1):269-72. doi: 10.3109/02713688709020103.
Because of reported differences in potency, recombinant DNA-derived human alpha interferons (IFNs) were reevaluated for use against acute Herpes Simplex Virus type 1 (HSV-1) infection of the rabbit eye. The IFNs used topically were IFN-alpha 2, (IFN-alpha 2) and a consensus of known human IFN-alpha s, designated IFN-alpha Con1. Prophylactic treatment with IFN-alpha Con1 at 1 or 15 X 10(6) U/eye/day beginning 48 hours before HSV-1 inoculation and therapeutic treatment with 5 or 15 X 10(6) U/eye/day beginning 4 hours after inoculation with either IFN-alpha Con1 or IFN-alpha 2 appeared to prevent or significantly reduce the development of corneal epithelial involvement. The effects were dose dependent with no evidence for decreased activity at the higher dose. The duration of HSV-1 shedding into tear film was not significantly reduced.
由于已报道的效价差异，对重组DNA衍生的人α干扰素（IFN）针对兔眼单纯疱疹病毒1型（HSV-1）急性感染的用途进行了重新评估。局部使用的干扰素为IFN-α2、（IFN-α2）以及已知人IFN-α的一种共识物，命名为IFN-αCon1。在HSV-1接种前48小时开始，以1或15×10⁶单位/眼/天的剂量用IFN-αCon1进行预防性治疗，以及在接种后4小时开始，用5或15×10⁶单位/眼/天的剂量用IFN-αCon1或IFN-α2进行治疗性治疗，似乎可以预防或显著减少角膜上皮受累的发展。这些效果呈剂量依赖性，没有证据表明在较高剂量下活性降低。HSV-1向泪膜中排出的持续时间没有显著缩短。
